Investigational Drug Information for Larotaxel
✉ Email this page to a colleague
What is the development status for investigational drug Larotaxel?
Larotaxel is an investigational drug.
There have been 7 clinical trials for Larotaxel.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2008.
The most common disease conditions in clinical trials are Breast Neoplasms, Pancreatic Neoplasms, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for Larotaxel
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,468 |
| WIPO Patent Applications | 947 |
| Japanese Patent Applications | 565 |
| Clinical Trial Progress | Phase 3 (2008-02-01) |
| Vendors | 27 |
Recent Clinical Trials for Larotaxel
| Title | Sponsor | Phase |
|---|---|---|
| Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer | Sanofi | Phase 3 |
| Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients | Sanofi | Phase 2 |
| Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen | Sanofi | Phase 3 |
Clinical Trial Summary for Larotaxel
Top disease conditions for Larotaxel
Top clinical trial sponsors for Larotaxel
US Patents for Larotaxel
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
